Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 608Pancreatic Neoplasms 371Carcinoma, Hepatocellular 284Stomach Neoplasms 236Rectal Neoplasms 173Colonic Neoplasms 162Carcinoma, Non-Small-Cell Lung 160Esophageal Neoplasms 158Breast Neoplasms 138Neoplasms 126Neoplasm Metastasis 123Ovarian Neoplasms 114Lung Neoplasms 104Cholangiocarcinoma 101Liver Neoplasms 95Gastrointestinal Neoplasms 93Melanoma 82Biliary Tract Neoplasms 74Prostatic Neoplasms 71Esophageal Squamous Cell Carcinoma 66Endometrial Neoplasms 66Sarcoma 54Squamous Cell Carcinoma of Head and Neck 53Carcinoma, Renal Cell 53Uterine Cervical Neoplasms 47Adenocarcinoma Of Esophagus 45Head and Neck Neoplasms 44Urinary Bladder Neoplasms 39Triple Negative Breast Neoplasms 37Gastrointestinal Stromal Tumors 34

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastroenteropancreatic Neuroendocrine Tumor × Gastrointestinal × 90 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡